Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Cyteir Therapeutics Inc | CYT | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.02 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.02 | 3.02 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.67 - 3.19 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 3.02 | USD |
Cyteir Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 108.71M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Cyteir Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/07/2024 | 15:31 | Edgar (US Regulatory) | Form 8-K - Current report |
| 3/07/2024 | 15:30 | Business Wire | Cyteir Announces Timeline for Voluntarily Delisting from.. |
| 3/05/2024 | 17:11 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/14/2024 | 18:36 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 2/13/2024 | 18:14 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 12/27/2023 | 15:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/14/2023 | 15:00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 12/07/2023 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/05/2023 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/22/2023 | 12:47 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 11/17/2023 | 15:01 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/06/2023 | 15:01 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 3.15 | 3.19 | 2.99 | 3.06 | 304,891 | -0.13 | -4.13% |
| 6 Months | 3.01 | 3.19 | 2.97 | 3.06 | 135,595 | 0.01 | 0.33% |
| 1 Year | 2.10 | 3.19 | 1.67 | 2.80 | 178,829 | 0.92 | 43.81% |
| 3 Years | 16.50 | 23.10 | 1.13 | 5.53 | 135,353 | -13.48 | -81.70% |
| 5 Years | 16.50 | 23.10 | 1.13 | 5.53 | 135,353 | -13.48 | -81.70% |
Cyteir Therapeutics Description
| Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing the next generation of precision oncology medicines that inhibit DNA damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Its lead program is CYT-0851, which is designed to exploit a novel synthetic lethality between overexpression of a family of DNA damaging enzymes called cytidine deaminases and functional inhibition of homologous recombination, a DNA repair pathway critical for the survival of some cancers. Its Pre-clinical program is CYT-1853, which is designed to exploit the same novel synthetic lethality targeted by CYT-085. |
